Life Science Update | May 2026

Why It Matters

These developments tighten oversight, reshape filing strategies, and signal heightened protection for biotech inventions, compelling companies to adjust IP workflows and budget for AI‑assisted counsel.

Key Takeaways

• AI-generated patent drafts lack error warnings, increasing liability risk
• Federal Circuit upholds gene‑therapy patent eligibility, expanding biotech protection
• USPTO’s PIER pilot forces early decision on PCT national stage
• New §101 guidance mandates SMED declarations for faster allowance
• Knobbe Martens wins LSPN Firm of the Year award

Pulse Analysis

Artificial intelligence is reshaping how life‑science companies prepare patent applications, delivering speed and cost savings that were previously unattainable. However, AI‑generated drafts often embed subtle errors without any disclaimer, and once filed with the USPTO those statements become part of the public record. Firms must therefore institute rigorous human review processes, invest in AI‑audit tools, and allocate legal resources to mitigate the risk of inadvertent claim scope loss or invalidity challenges.

The Federal Circuit’s decision in Regenexbio Inc. v. Sarepta Therapeutics confirms that genetically engineered host cells used in gene‑therapy are patent‑eligible, reinforcing the protective moat around high‑value biologics. Simultaneously, the USPTO’s new PIER pilot program forces applicants to make an early go‑/‑no‑go decision on selected PCT national‑stage filings, accelerating the examination timeline but also raising the stakes of a missed response. The April 2026 memorandum further codifies the use of separate SMED (Subject Matter Eligibility Declarations) to address §101 rejections, encouraging clearer articulation of real‑world benefits and potentially improving allowance rates for complex biotech inventions.

For practitioners, these shifts translate into a need for tighter internal workflows, from AI oversight to rapid response teams for PIER notifications. Companies should revisit budgeting to cover additional counsel hours and consider integrating SMED drafting into standard claim preparation. The industry also takes note of Knobbe Martens’ recognition as Life Sciences Prosecution Firm of the Year, highlighting the competitive advantage of firms that excel in navigating this evolving patent landscape. Aligning IP strategy with these regulatory and judicial trends will be critical for sustaining innovation pipelines and protecting market share.